Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial von Geurts, V.C.M., Voorwerk, L., Balduzzi, S., Salgado, R., Van de Vijver, K., van Dongen, M.G.J., Kemper, I., Mandjes, I.A.M., Heuver, M., Sparreboom, W., Haanen, J.B.A.G., Sonke, G.S., Horlings, H.M., Kok, M.

Volltext

90TiP Monalizumab and trastuzumab in metastatic HER2-positive breast cancer: MIMOSA-trial von Geurts, V.C.M., Voorwerk, L., Sikorska, K., Van Dongen, M.G., Kemper, I., Mandjes, I.A.M., Haanen, J.B.A.G., Sonke, G.S., Kok, M.

Volltext

120P Impact of PET-CT and neoadjuvant systemic treatment in patients with stage I HER2+ breast cancer von van Olmen, J.P., Geurts, V.C.M., Drukker, C.A., Peeters, M-J.T.F.D. Vrancken, Kok, M., van Duijnhoven, F.H.

Volltext